)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
Nurix Therapeutics (NRIX) investor relations material
Nurix Therapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary9 Oct, 2025
Executive summary
Focused on targeted protein degradation therapies for cancer and autoimmune diseases, leveraging the DEL-AI platform and multiple strategic collaborations.
Lead clinical programs include bexobrutideg (NX-5948), zelebrudomide (NX-2127), and NX-1607, all in early clinical development.
Initiation of pivotal trials for bexobrutideg in relapsed/refractory CLL planned for H2 2025, with both accelerated and full approval strategies outlined.
Presented strong preclinical and clinical data for pipeline assets, including GS-6791 (IRAK4 degrader) and bexobrutideg in CLL and Waldenström macroglobulinemia.
Collaborations with Gilead, Sanofi, and Pfizer provide significant non-dilutive funding and future milestone potential.
Financial highlights
Total revenue for the nine months ended August 31, 2025, was $70.4 million, up from $41.3 million year-over-year, driven by $30.0 million in license revenue from Sanofi.
Revenue for Q3 2025 was $7.9 million, down from $12.6 million in Q3 2024, mainly due to the end of certain Sanofi collaboration terms.
Net loss for the nine months ended August 31, 2025, was $186.2 million, compared to $135.0 million for the same period in 2024.
Net loss for Q3 2025 was $86.4 million ($1.03 per share), compared to $49.0 million ($0.67 per share) in Q3 2024.
Cash, cash equivalents, and marketable securities totaled $428.8 million as of August 31, 2025.
Outlook and guidance
Current cash and investments are expected to fund operations for at least the next 12 months.
Pivotal trials for bexobrutideg in CLL to begin in H2 2025, with additional clinical updates expected.
Substantial additional funding will be required to support long-term plans and commercialization.
Anticipates continued increases in R&D and G&A expenses as clinical programs advance and infrastructure expands.
Plans to support bexobrutideg development in autoimmune and inflammatory diseases, with Phase 1b and healthy volunteer studies ongoing.
Rationale for dual bexobrutideg approval path?
Cash runway given increased R&D spend?
GS-6791: How does degradation improve efficacy?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Nurix Therapeutics earnings date
Q4 202513 Feb, 2026
Next Nurix Therapeutics earnings date
Q4 202513 Feb, 2026
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
)
Edge19 Sep 2025
American Express: An Empire of Plastic
How history, brand, and structure have steadily built American Express' moat, and why Warren Buffett still calls it a one-of-a-kind business.
Frequently asked questions
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule and cell therapies. These therapies are designed to treat cancer and inflammatory diseases by modulating cellular protein levels. Nurix leverages its proprietary DELigase platform, which involves the use of E3 ligases within the ubiquitin-proteasome system, to either decrease or increase protein levels selectively. The company’s drug development strategy includes both targeted protein degraders and ligase inhibitors, addressing unmet medical needs in hematology-oncology, immuno-oncology, and inflammation. The company is headquartered in San Francisco, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage